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replacement: Mechanisms and future prognostic implicationsWilliam M. Yarbrough, MD,a Rupak Mukherjee, PhD,a John S. Ikonomidis, MD, PhD,a
Michael R. Zile, MD,b,c and Francis G. Spinale, MD, PhDa,cAortic valve stenosis is a common cause of left ventricular pressure overload, a pathologic process that elicits myocyte hy-
pertrophy and alterations in extracellular matrix composition, both of which contribute to increases in left ventricular stiff-
ness. However, clinical and animal studies suggest that increased myocardial extracellular matrix fibrillar collagen content
occurs later in the time course of left ventricular pressure overload at a time coincident with severe abnormalities in diastolic
function followed by the development of symptomatic heart failure. Aortic valve replacement remains the most effective
treatment for elimination of chronic pressure overload secondary to aortic stenosis but has traditionally been recommended
only after the onset of clinical symptoms. Long-term follow-up of patients with symptomatic aortic stenosis after aortic valve
replacement suggests that valve replacement may not result in complete reversal of the maladaptive changes that occur
within the myocardial extracellular matrix secondary to the pressure overload state. To the contrary, residual left ventricular
extracellular matrix abnormalities such as these are likely responsible for persistent abnormalities in diastolic function and
increased morbidity and mortality after aortic valve replacement. Defining the mechanisms and pathways responsible for
regulating the myocardial extracellular matrix during the natural history of aortic stenosis may provide a means by which
to detect crucial structural milestones and thereby permit more precise identification of the development of maladaptive left
ventricular remodeling. (J Thorac Cardiovasc Surg 2012;143:656-64)Aortic stenosis (AS) is a common disease in which failure of
the aortic valve to completely open imposes an abnormally
high-pressure load on the left ventricle (LV). Irrespective of
the cause of AS, the ensuing pressure overload results in the
manifestation of 2 distinct but overlapping processes.1-3
The first process is characterized by concentric left
ventricular hypertrophy (LVH), and, as demonstrated by the
Law of Laplace, the increased wall thickness and mass act
to limit the increase in wall stress created by the AS-
induced pressure overload state.2,4 The second process
occurs within the myocardial extracellular matrix (ECM)
and leads to progressive myocardial fibrosis, reduced
ventricular compliance, and impairments in diastolic filling
(ie, diastolic dysfunction).5-10 It is this second phase of
progressive LV myocardial fibrosis that contributes to the
progression of LV diastolic dysfunction and eventually to
the presentation of the signs and symptomsofheart failure.6,10
Aortic valve replacement (AVR) remains the single most
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656 The Journal of Thoracic and Cardiovascular Surgpressure overload in patients with AS. The current guide-
lines for AVR in patients with AS include those with severe
AS and the presence of symptoms such as heart failure.11 In
the absence of precluding factors, the presence of symptoms
with AS mandates consideration for AVR to avoid a 25%
yearly mortality rate associated with disease of this ex-
tent.12 However, there are several lines of evidence to sug-
gest that this paradigm for timing of AVR could be
improved. First, forestalling AVR until heart failure symp-
toms manifest implies that the development of the decom-
pensated maladaptive phase has already occurred. As
a result, significant and deleterious structural LV myocar-
dial remodeling has likely already ensued along with the at-
tendant changes in LV diastolic function.6 Although
imaging and functional studies such as echocardiography
can quantify indices of LV diastolic function (eg, filling
rates and relaxation times), abnormalities in these indices
will only become detectable once the structural changes
within the myocardium and in particular the myocardial
ECM have already become manifest. Thus, once physiolog-
ically and subsequently clinically significant LV diastolic
dysfunction has occurred with AS, significant and irrevers-
ible changes within the myocardial ECM have been estab-
lished. Second, significant clinical and experimental
evidence exists to suggest that when AVR is performed
only after the development of LV diastolic dysfunction
and heart failure symptoms, the LV myocardial remodeling
process that ensued from long-standing AS may not be
readily reversible.5-7,13 Myocardial fibrosis secondary to
long-standing and progressive AS may persist for years af-
ter AVR6 and can contribute to the persistence of postoper-
ative heart failure symptoms.13,14 Therefore, although theery c March 2012
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Duse of current guidelines to determine appropriate timing of
AVR has yielded reasonable surgical outcomes, this
approach may result in the incomplete reversal of the
deleterious changes present within the LV myocardial
matrix of patients with symptomatic AS.
To improve the timing for AVR, it is essential to identify
the mechanistic underpinnings that contribute to the devel-
opment of maladaptive LV remodeling. Because increased
myocardial fibrosis and myocardial stiffness represent
hallmarks of maladaptive LV remodeling with AS,10,15
the determinants of ECM remodeling likely play an
instrumental role. Although elucidation of molecular and
biochemical pathways that contribute to myocardial ECM
remodeling, fibrosis, and LV dysfunction will provide
clinically relevant prognostic information, translation of
these basic ECM pathways into diagnostic and prognostic
applications that can be used to direct appropriate timing
for AVR within the context of AS is necessary.
Accordingly, the purpose of this review is 2-fold. The first
goal is to examine the results obtained from clinical and rel-
evant preclinical studies of AS and AVR with respect to ad-
verse LV ECM remodeling and the attendant effects on LV
form and function. Although significant structural and ECM
changes occur within the aortic valve itself with AS, the fo-
cus of this review is to examine the consequences of the
pressure overload with AS, as it applies to the myocardium.
The specific focus of this goal will be to examine the tem-
poral and structural LV remodeling that exists in the ECM
compartments during the development and progression of
AS-induced LVH and heart failure and after relief from
this pressure overload state with AVR. We will attempt to
coalesce the findings generated in these studies to provide
an updated hypothesis of the molecular pathways that reg-
ulate myocardial ECM remodeling with AS and after
AVR. The second goal of this review is to examine molec-
ular pathways that contribute to myocardial ECM structureThe Journal of Thoracic and Caand composition and identify those pathways that may yield
relevant biomarker signatures with respect to the natural
history of AS. This goal will allow development of methods
to improve the timing of AVR.
CLINICAL INVESTIGATIONS OFAORTIC
STENOSIS
Although increased myocyte size is one critical feature of
pressure overload-induced LV remodeling, the develop-
ment of abnormalities within the ECM represents a malad-
aptive structural milestone in the progression of
decompensated heart failure.5-7,16-18 Changes in ECM
composition and structure and accumulation of ECM
components, such as increased fibrillar collagen content,
have been shown to impair LV diastolic filling and
decrease LV distensibility in hypertensive heart
disease16,17 and clinical AS.7,10,13,19,20 These pressure
overload-induced changes in ECM structure and composi-
tion play a mechanistic role in the progression of heart fail-
ure. There are several clinical studies that support this
conclusion and clearly relate myocardial ECM content to
LV diastolic mechanics during the progression of AS-
induced pressure overload and during the regression of
AS-induced pressure overload after AVR. These investiga-
tions are briefly described next.
A specific set of cellular and extracellular events occur
during the development of AS and after AVR. Investigators
from the University Hospital, Zurich, Switzerland, provided
much of what is known regarding the effects of clinical aor-
tic valve stenosis on myocardial structure and function be-
fore and after AVR.5-8 Patients with AS demonstrated
significantly increased LV myocardial interstitial fibrosis
compared with control patients.6-8 Moreover, LV
relaxation, filling, and stiffness were abnormal in patients
with AS.6 However, there were no changes in LV systolic
performance in patients with AS.5,6 Thus, these
investigations are important in that they linked changes
within the LV extracellular compartment with the clinical
syndrome of pressure overload-induced diastolic dysfunc-
tion and heart failure. These same investigators examined
the effects of AVR on components of the myocardial
ECM.6 Specifically, AVR was associated with changes in
interstitial fibrosis at both early (22  8 months) and late
(81  24 months) time points compared with preoperative
values. Interstitial fibrosis remained elevated over control
values late after AVR and failed to normalize (Figure 1).
Whether the persistent LV structural abnormalities noted
by these investigators achieve clinical significance remains
a matter of debate; however, it is noteworthy that these col-
leagues demonstrated that approximately 20% of patients
with AS exhibited some degree of exercise intolerance 5
to 10 years after AVR.14 A more recent clinical investiga-
tion conducted by Weidemann and associates15 lends cre-
dence to the assertion made by these initial investigatorsrdiovascular Surgery c Volume 143, Number 3 657
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FIGURE 1. Villari and colleagues6 demonstrated that regression of
AS-induced cellular and extracellular abnormalities occurs in a time-
dependent manner after AVR. Moreover, elimination of the pressure
overload state failed to achieve normalization of myocyte diameter and in-
terstitial fibrosis. Expressed as a percentage change from control values,
AVR was associated with significant reductions in muscle fiber diameter
at both early (22  8 months) and late (81  24 months) time points com-
pared with preoperative values; however, muscle fiber diameter remained
significantly elevated over control values late after AVR. Values for inter-
stitial fibrosis increased early after AVR compared with preoperative
values. This increase was likely ‘‘relative’’ and a result of a concomitant
early reduction in myocyte mass as opposed to an increase in collagen syn-
thesis after AVR. Values for interstitial fibrosis remained significantly ele-
vated above those observed in the control group late after AVR. Data are
presented as themean and the standard error of themean andweremodified
from Villari and colleagues6 (*P<.05 vs control,þP<.05 vs preoperative,
#P<.05 vs early).
FIGURE 2. Increasing degrees of myocardial fibrosis secondary to aortic
valve disease (as assessed histologically) are associated with progressive
reductions in survival in patients treated with AVR using traditional criteria
for intervention (ie, symptom onset). Modified from Azevedo and
colleagues.13
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cardial fibrosis. In their prospective follow-up study,Weide-
mann and colleagues determined that the degree of
myocardial fibrosis (biopsy taken at the time of operative
intervention) correlated more closely with the preoperative
New York Heart Association class than LVejection fraction
or aortic valve area in patients undergoing valve replace-
ment for AS. Moreover, they determined that AVR provided
less functional improvement in patients with AS and severe
fibrosis compared with those patients with lesser degrees of658 The Journal of Thoracic and Cardiovascular Surgfibrosis. Although their period of follow-up (9 months) was
substantially shorter than that described in the preceding
clinical investigations, it is noteworthy that these authors
used magnetic resonance imaging studies to demonstrate
that AVR failed to reduce fibrosis in the majority of patients
with severe fibrosis at baseline. Azevedo and colleagues13
similarly used histopathology and magnetic resonance im-
aging to assess AS-induced myocardial fibrosis. They dem-
onstrated that greater degrees of myocardial fibrosis were
associated with decreased survival after AVR (Figure 2).
Taken together, the results of these clinical investigations
suggest that consideration for valve replacement before
the onset of adverse myocardial ECM sequelae may repre-
sent a worthwhile goal in patients with severe but asymp-
tomatic AS. Moreover, consideration for such a deviation
from current practice is only strengthened by the realization
that isolated AVR has become a relatively safe operation as-
sociated with an overall mortality rate approaching 3%,
a value far less than that observed during the conduction
of the landmark clinical investigations described above.5-7
It is noteworthy that the degree of observed myocardial
fibrosis secondary to AS appears to differ among patients
with preserved LV systolic function and those with LV sys-
tolic dysfunction. As alluded to above, Weidemann and col-
leagues15 assessed LV myocardial fibrosis in patients with
severe AS and preserved LV ejection fraction. The degree
of fibrosis observed among these patients varied widely
fromminimal to severe. However, it is likely that this dispar-
ity diminishes as LV systolic function deteriorates as a result
of long-standing LV pressure overload. Investigations ex-
amining the effects of long-standing pressure overload sec-
ondary to hypertensive heart disease17 andAS10 suggest that
fibrosis is increased in patients with reduced LV ejection
fraction. For example, Querejeta and colleagues17 demon-
strated that collagen deposition was greater in patientsery c March 2012
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with hypertension alone. Hein and colleagues10 examined
the transition from compensated LVH to heart failure in pa-
tients with AS and demonstrated that the fibrotic response
was greater in patients with reduced LV ejection fractions.
Thus, although the degree of observed LVmyocardial fibro-
sis may vary among patients with preserved LV systolic
function and severe pressure overload, it seems that marked
fibrosis tends to accompany patients with LV systolic dys-
function and pressure overload. Such a realization high-
lights that fact that progressive myocardial fibrosis
contributes to the signs and symptoms of heart failure sec-
ondary to long-standing pressure overload.
On assessment of the clinical investigations included in
this review, it would seem reasonable to assume that as
the aortic valve area decreases or the transvalvular mean
gradient increases that LV fibrosis would increase in a linear
fashion. However, this does not seem to be the case. The
majority of the investigations considered above did not in-
clude individual subject values for these parameters, and
this renders efforts to assess correlation problematic. In an
effort to address this issue, we analyzed individual subject
data points provided in a clinical investigation conducted
by Peterson and colleagues.9 These investigators assessed
patients with moderate to severe AS, and they included in-
dividual subject values for LVejection fraction, aortic valve
area, transvalvular mean gradient, and myocardial stiffness.
Although it is true that myocardial stiffness can be altered
by both cellular and extracellular characteristics, it seems
reasonable to consider myocardial stiffness as a surrogate
for myocardial fibrosis. Accordingly, on the basis of infor-
mation provided by Peterson and colleagues, we performed
linear regression analyses to determine whether relation-
ships existed among LV ejection fraction, aortic valve
area, and transvalvular mean gradient with myocardial stiff-
ness. There were no significant relationships between these
parameters and myocardial stiffness. These findings are in
keeping with those of past investigations. For example,
Krayenbuehl and colleagues7 found no significant correla-
tion between LVejection fraction and percentage of intersti-
tial fibrosis (as assessed by histology) in patients with
severe AS. However, it should be noted that these studies in-
cluded patients with preserved LV systolic function as as-
sessed by LV ejection fraction. It is certainly possible that
had patients with decompensated heart failure been in-
cluded, a correlation might have been observed. Therefore,
because there seems to be no clear relationship between fi-
brosis and LVejection fraction, aortic valve area, and trans-
valvular mean gradient in patients with AS, a new effort
should be made to identify an alternative strategy by which
to monitor patients with AS and to guide timeliness of
surgical intervention. As evidenced by the data recently re-
ported by Azevedo and colleagues,13 further improvements
can likely be made in reducing mortality and postoperativeThe Journal of Thoracic and Caoutcomes in patients undergoing AVR for AS, and it is
likely that the key to accomplishing this task lies within
the myocardial ECM.
MODELS OF CHRONIC PRESSURE OVERLOAD
Short of carrying out serial myocardial biopsies in clini-
cal settings, it is difficult to assess the effects of chronic LV
pressure overload on the LV myocardial ECM. It is fortu-
nate that preclinical investigations describing the effects
of chronic pressure overload on myocardial structure and
function in large animals do exist,21-24 although they are
relatively few in number in comparison with small animal
pressure overload constructs. Because gradual increases in
the pressure overload state can be carried out more easily
in large animals, these models provide an opportunity to
closely recapitulate the clinical context of AS. For
example, Moorjani and collaborators21 banded sheep with
variable constrictors and gradually increased the degree of
stenosis to achieve peak terminal gradients approximating
80 mm Hg. LV mass doubled within 1 month after the onset
of progressive and sustained aortic constriction. Investiga-
tors in Leipzig, Germany, are also credited with establishing
a chronic ovine model of chronic pressure overload.22
Supracoronary banding was carried out in growing sheep
to mimic compensated LV pressure overload, and LV mor-
phologic assessments were carried out approximately 8
months later. These assessments revealed significant in-
creases in myocardial fiber index, LV mass index, and
wall thickness compared with baseline and control values.
The importance of these experimental models cannot be
overstated. Because of the models’ ability to recapitulate
the common clinical scenario of compensated AS, an op-
portunity exists in which changes in myocardial ECM prop-
erties secondary to chronic pressure overload can be serially
assessed. Thus, it seems likely that similar model constructs
can be used to more closely identify critical ECM events
that are responsible for igniting maladaptive LV remodeling
events in the setting of chronic pressure overload. Taken to-
gether, the results of these experimental and clinical studies
suggest that some degree of plasticity exists in the progres-
sion of morphologic changes that occur secondary to pres-
sure overload. However, the time point at which plasticity is
lost within the myocardial ECM, and reversibility of malad-
aptive myocardial changes is no longer possible, remains
elusive. Identification of specific surrogate markers within
the peripheral circulation that are reflective of adverse
ECM events may provide an avenue for the identification
of just such a transition point.
LEFT VENTRICULAR PRESSURE OVERLOAD
AND IDENTIFICATION OFABNORMAL
EXTRACELLULAR MATRIX PATHWAYS
Biomarkers are measurable serum proteins that are asso-
ciated with various disease states, including AS. Forrdiovascular Surgery c Volume 143, Number 3 659
TABLE 1. Potential biomarkers for tracking aortic stenosis
Osteopontin  Glycophosphoprotein that stimulates differentiation of myofibroblasts into osteoblasts.
 Serum levels are increased in AS.56
C-reactive protein  Acute-phase reactant that is increased in inflammatory states (ie, AS).
 Serum levels can be used to predict symptom severity associated with AS.26
BNP  Levels of this endogenous cardiac hormone correlate with New York Heart Association symptom class and are elevated in
patients with AS-induced pressure overload.25
TGF-b  Cytokine that induces fibroblast activation and collagen production/fibrosis in response to pressure overload.30,33
CT1  Cytokine derived from cardiac fibroblasts34 that induces myocyte hypertrophy35 and stimulates fibroblast growth.36
Collagen-derived peptides
(PIP, PIIIP, CITP)
 Because serum values of collagen-derived peptides reflect collagen synthesis and degradation, their measured abundances
may be used to assess the severity and progression of pressure overload states.43
MMPs  Zinc-dependent proteolytic enzymes that degrade the myocardial ECM.
 Influence bioactive signaling pathways by processing cytokines/cytokine receptors.46,57
TIMPs  Endogenous proteins that bind to MMPs and regulate their proteolytic activity.
 TIMP-1 and 2 have been most extensively investigated in the setting of heart failure.46,47,58
AS, Aortic stenosis; BNP, B-type natriuretic peptide; TGF, transforming growth factor; CT, cardiotrophin; ECM, extracellular matrix; CITP, collagen I telopeptide; PIP,
procollagen type I carboxy-terminal propeptide; PIIIP, procollagen type III amino-terminal propeptide; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of matrix
metalloproteinase.
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measurable and reproducible among separate laboratories,
and should provide clinicians with at least some informa-
tion regarding disease prognosis and treatment efficacy, or
lack thereof. The past decade is marked by a host of clinical
and experimental investigations aimed at identifying bio-
markers geared toward identification of patients with clini-
cally significant AS who may benefit from AVR, and these
include osteopontin, C-reactive protein, and B-type natri-
uretic peptide (BNP).25-28 For example, clinical studies
performed by Gerber and associates25 provided evidence
that BNPmay be used to monitor and reflect symptom onset
in patients with AS. Their studies demonstrated that yearly
increases in BNP values were greater in patients with AS
who developed symptoms compared with those who did
not. Furthermore, these investigators established that the
typical parameters used to direct therapeutic intervention
for patients with AS, such as aortic valve area, transvalvular
peak velocity, and LV ejection fraction, were less reliable
than increases in BNP in predicting symptom onset. Never-
dal and colleagues29 demonstrated that plasma BNP values
decreased after AVR and that the observed decrease corre-
lated with regression in the LV mass index. However, it
should be noted that although biomarkers such as these
may be used to assess the severity of clinical AS, detection
of robust serum values likely corresponds to the latter stages
of the disease process. In other words, marked elevations of
C-reactive protein and BNP in the setting of AS likely occur
only after the transition from adaptive to maladaptive LV re-
modeling. Accordingly, it is imperative that biomarkers
with greater sensitivity for identification of just such a tran-
sition be identified to more accurately time AVR for patients
with AS. Identification of such a critical time point would
be more likely to facilitate complete regression of adverse
myocardial cellular and extracellular changes that ensue
secondary to long-standing pressure overload. Because660 The Journal of Thoracic and Cardiovascular Surgmyocyte hypertrophy represents an early and relatively re-
versible event in the progression of pressure overload in-
duced myocardial remodeling, it seems appropriate to
focus attention on the identification of biomarkers that are
more closely associated with remodeling of the myocardial
ECM, that is, those pertaining to fibrosis (Table 1). Such
biomarkers include, but are not limited to, transforming
growth factor (TGF)-b, cardiotrophin (CT)-1, collagen-
derived peptides (carboxy-terminal propeptide of procolla-
gen I and carboxy-terminal telopeptide of procollagen I),
matrix metalloproteinases (MMPs), and tissue inhibitors
of the matrix metalloproteinases (TIMPs).
TRANSFORMING GROWTH FACTOR-b1
TGF-b is a multifunctional cytokine that is responsible
for inducing collagen production and known to regulate cel-
lular proliferation and differentiation in both normal ho-
meostatic pathways and numerous disease states.30,31 Past
experimental investigations have implicated this protein
as a critical entity in the orchestration of deleterious
changes within the myocardial cellular and extracellular
compartments in the setting of pressure overload.32,33 For
example, Kuwahara and colleagues applied a TGF-
b blocking antibody to a rodent model of pressure
overload and bolstered proof of concept evidence that
TGF-b plays a crucial role in carrying out the elaboration
of ECM components in the setting of pressure overload.33
These investigators observed inhibition of fibroblast activa-
tion, collagen messenger RNA (mRNA) induction, and fi-
brosis in pressure-overloaded rodents treated with the
neutralizing antibody. In an investigation that highlighted
TGF-b as a potential biomarker, Villar and associates dem-
onstrated that plasma levels of TGF-bwere significantly in-
creased in patients with AS and in mice subjected to
transaortic constriction compared with controls.32 More-
over, plasma TGF-b levels positively correlated withery c March 2012
Yarbrough et al Acquired Cardiovascular Diseasetransvalvular mean gradients and representative parameters
for LV mass in patients with AS before and after AVR. A
positive correlation between TGF-b and genes encoding
collagen I and III was also identified.A
C
DCARDIOTROPHIN-1
Cardiac CT-1 is a cytokine that is primarily derived from
cardiac fibroblasts34 and that has been shown to induce my-
ocyte hypertrophy35 and stimulate fibroblast growth.36 A re-
cent clinical investigation by Lopez and colleagues37
demonstrated that CT-1 could be used as a biomarker to as-
sess the severity and progression of LV pressure overload
secondary to hypertensive heart disease. Specifically, these
investigators studied patients with hypertension and no car-
diac disease, patients with hypertension and LVH, and pa-
tients with hypertension, LVH, and signs of chronic heart
failure. Plasma CT-1 levels were assessed and found to in-
crease progressively with increasing stages of cardiac dys-
function. Moreover, CT-1 positively and negatively
correlated with LV mass and ejection fraction, respectively,
and the authors concluded that CT-1 was a more sensitive
biomarker than the amino-terminal pro-BNP for the identi-
fication of heart failure. This latter revelation supports the
concept that biomarkers reflective of ongoing ECM activi-
ties occurring secondary to pressure overload may be of
more value than biomarkers such as BNP that surface and
peak only after maladaptive LV myocardial remodeling
has occurred. Although this study pertained to pressure
overload secondary to hypertension, it seems reasonable
to assume that similar results would be obtained if the study
population included patients with pressure overload sec-
ondary to AS; however, this remains to be proven.COLLAGEN-DERIVED PEPTIDES
The myocardial ECM contains collagen types I and III.38
After the synthesis of procollagen types I and III within
myocardial fibroblasts, these large peptides are released
into the extracellular compartment with intact amino- and
carboxy-propeptide terminals. Subsequent cleavage by spe-
cific matrix proteases generates collagen types I and III
fibers and their respective propeptide fragments in a stoi-
chiometric ratio of 1:1. Specifically, the carboxy-terminal
and amino-terminal propeptides of procollagen types I
and III, respectively, are cleaved and released into the serum
yielding collagen types I and III. Because carboxy-terminal
and amino-terminal propeptides of procollagen types I and
III values, respectively, can be measured in the serum, their
values can be used as a surrogate to reflect the overall de-
gree of collagen synthesis. Likewise, collagen type I fibers
are degraded by collagenase in a stoichiometric ratio of 1:1.
Of note, the small telopeptides (for example, collagen I
telopeptide) resulting from the proteolytic processing of
collagen type I can also be measured within the serum,The Journal of Thoracic and Caand the values can be used to assess the degree of collagen
degradation.
Past studies demonstrate that accumulation of myocar-
dial collagen accompanies chronic pressure overload
states6,39-41 and that increased collagen accumulation can
result in increased myocardial stiffness.42 Because
collagen-derived peptides enter the circulation in quanti-
ties proportional to the amount of collagen synthesis and
degradation that is simultaneously occurring,38 Lopez
and colleagues43 surmised that measurement of these se-
rum peptides might be used as a means by which to assess
the severity and progression of pressure overload states.
This supposition was based on past studies that assessed
and noted differential serum concentrations of carboxy-
terminal propeptide (synthesis) and telopeptide (degrada-
tion) fragments of procollagen type I in normal and
hypertensive patients44 and rats.45 Specifically, carboxy-
terminal propeptide was increased in the serum of hyper-
tensive patients44 and spontaneously hypertensive rats,45
whereas serum telopeptide remained unchanged, thus re-
flecting a shift in the collagen synthesis/degradation ratio
favoring collagen accumulation. Because carboxy-
terminal propeptide is not myocardial-specific, these inves-
tigators assessed the amount of this serum biomarker from
both coronary sinus and peripheral blood of hypertensive
patients to establish marker specificity for myocardial
collagen accumulation.17 Values for carboxy-terminal pro-
peptide were higher in coronary sinus serum of hyperten-
sive patients compared with peripheral serum but were
not in healthy patients, indicating that measurement of
collagen-derived serum peptides may be used as a noninva-
sive way to assess and follow myocardial fibrosis second-
ary to pressure overload. Heymans and colleagues41
assessed cardiac mRNA expression for collagen types I
and III and for collagen synthesis transcripts in patients
with chronic pressure overload secondary to AS. Collagen
a1 types I and III mRNA levels were significantly higher
in patients with AS compared with control patients, as
were levels for lysine and proline hydroxylases and procol-
lagen type III N-endopeptidase. It is not surprising that
these values were associated with significant increases in
total myocardial collagen, with the greatest increase ob-
served at the level of the endocardium. Taken together,
the results of these investigations suggest that a role may
exist for the serum determination of collagen-derived pep-
tides as a means by which to assess disease severity in the
setting of chronic pressure overload.
MATRIX METALLOPROTEINASES AND TISSUE
INHIBITORS OF MATRIX
METALLOPROTEINASES
The MMPs are an endogenous family of zinc-dependent
enzymes that are intimately associated ECM remodeling
processes in numerous disease states, including pressurerdiovascular Surgery c Volume 143, Number 3 661
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on their substrate specificities. For example, the collage-
nases include MMP-1 and 8 and the gelatinases include
MMP-2 and 9.46 Increases in the plasma levels of MMPs
from this latter subgroup have recently been used to predict
LV diastolic dysfunction in patients with hypertension16
and are particularly pertinent species with respect to this pa-
thology. Although MMPs carry out numerous functions,
none is more important than the enzymatic degradation of
collagen and other components of the ECM initiated by
this family of enzymes.
Under normal circumstances, the TIMPs appropriately
counter MMP activity and maintain basal, nonpathologic
turnover of the ECM. However, past clinical and experi-
mental studies demonstrate that chronic pressure overload
alters this delicate balance and may be partially responsible
for the deleterious myocardial changes associated with this
disease state.22,24,41,47-50 Of the 4 TIMP proteins known to
exist, TIMP-4 is remarkable in that it is highly expressed
within the myocardium.51 TIMP-4 protein levels have
been shown to be increased in the plasma and myocardium
of patients with LV pressure overload.18,52 Although TIMPs
bind tightly to and inhibit the majority of theMMP proteins,
differences in their inhibitory profiles do exist. For instance,
TIMP-1 best inhibits MMP-9 and TIMP-4 best inhibits
MMP-2.53 These differences suggest that modulation of
specific TIMP proteins may have therapeutic potential in
modulating LV remodeling secondary to chronic pressure
overload.
Past efforts aimed at more clearly defining the
MMP:TIMP balance in the context of LV pressure overload
have demonstrated that some degree of plasticity exists. For
example, Walther and associates24 applied supracoronary
bands to sheep to recapitulate compensated LVH in an effort
to assess ECM gene expression. This technique resulted in
a near doubling of the LV mass index and was associated
with significant increases in MMP-1, 2, 3, and 9 and
TIMP-1 and 2 gene expression relative to baseline values.
The supracoronary bands, which generated a maximum
pressure gradient of 56.8  4.7 mm Hg, were subsequently
removed to reverse the pressure overload state, and com-
plete regression of gene expression levels and myocyte
hypertrophy was observed.24 Complete reversibility of the
latter parameter contrasts the persistent, albeit subtle, cellu-
lar changes observed in the clinical investigations carried
out by researchers at the University Hospital in Zurich,
Switzerland,6-8 as described above. Perhaps this
discrepancy is secondary to the fact that ovine aortic
banding achieved a relatively moderate degree of pressure
overload in comparison with those patients with severe
and long-standing AS included in past clinical investiga-
tions. Nevertheless, Walther and colleagues’ animal inves-
tigation proved to be instrumental in demonstrating that
alterations in gene expression occur within the ECM during662 The Journal of Thoracic and Cardiovascular Surginduction of LVH and after resolution of the pressure over-
load state.
The importance of MMP/TIMP balance in the progres-
sion of chronic pressure overload has also been investigated
in clinical settings.18,41,47,50 Although the majority of these
clinical studies focused on patients with hypertensive heart
disease,41,47,50 Fielitz and associates18 assessed the regula-
tion of MMPs and TIMPs in patients with severe and long-
standing AS. These investigators obtained myocardial
biopsies from patients undergoing AVR for AS and quanti-
fied mRNA expression for various MMPs and TIMPs, as
well as MMP and TIMP protein levels. mRNA expression
and protein levels for MMP-2 and extracellular matrix met-
alloproteinase inducer were significantly greater than those
values obtained from the control hearts, whereas MMP-9
and TIMP-1 mRNA and protein levels were decreased.
Although TIMP-4 mRNA expression was not increased rel-
ative to control values, TIMP-4 protein levels were, perhaps
as a result of some degree of post-transcriptional modula-
tion. With respect to the MMP/TIMP protein level ratio in
the setting of severe AS, the overall balance appeared
shifted toward MMP inhibition, thereby favoring collagen
accumulation.
PHARMACOLOGIC STRATEGIES, CLINICAL
IMPLICATIONS, AND FUTURE DIRECTIONS
Recent clinical investigations suggest that pharmaco-
logic intervention can influence the degree of observed
LV mass regression in patients with LV pressure overload.
For instance, Devereux and colleagues54 demonstrated
that modulation of the renin-angiotensin system using an-
giotensin receptor blockade (ARB) achieved greater LV
mass regression than administration of conventional
beta-blockade therapy in patients with arterial hyperten-
sion and LVH. On the basis of these data, it would
seem likely that a similar pharmacologic strategy could
be used to achieve like results in the postoperative man-
agement of patient undergoing AVR for AS. Indeed,
Dahl and colleagues55 observed just such a beneficial re-
sult in their single-center prospective randomized and
blinded investigation. Specifically, these investigators ap-
plied ARB to patients undergoing AVR for AS and com-
pared their postoperative LV mass indices against those
patients receiving conventional medical therapy after
AVR for AS. One year later, LV mass index was signifi-
cantly lower in the ARB group. It is noteworthy that de-
spite these results, there is at present no uniformity with
respect to recommended pharmacologic interventions
post-AVR. Moreover, no strategies exist that specifically
target adverse matrix remodeling that occurs with AS
and persists after AVR. Thus, combining potential bio-
markers of matrix remodeling with more standardized
pharmacologic protocols may provide an important future
direction.ery c March 2012
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FIGURE 3. The hypothetic schematic depicts deterioration in diastolic
function and an increase in myocyte hypertrophy and myocardial fibrosis
over time and in the setting of AS-induced progressive pressure overload.
Current management paradigms advocate AVR for patients with severe AS
and associated symptoms, namely, angina, syncope, and chronic heart fail-
ure. However, AVR carried out only after symptom onset likely fails to re-
verse the maladaptive ECM remodeling that has already occurred.
Identification of a biomarker capable of heralding the transition from
AS-induced adaptive to maladaptive ECM remodeling processes may
have therapeutic value. Specifically, identification of such a biomarker
may be used to direct more timely elimination of the pressure overload
state, thus optimizing the chances for normalization within the ECM and
improved postoperative outcomes. AS, Aortic stenosis; AV, aortic valve;
AVR, aortic valve replacement; ECM, extracellular matrix; LVH, left ven-
tricular hypertrophy.
Yarbrough et al Acquired Cardiovascular Disease
A
C
DCONCLUSIONS
Although forestalling AVR until the onset of symptoms
has proven to be a relatively successful strategy for patients
with severe AS for many years, it is apparent that interven-
tion delayed until this time point fails to achieve complete
regression of maladaptive changes that occur within the
myocardial ECM. Persistence of the products of myocardial
ECM elaboration secondary to ASmay translate into a post-
operative clinical condition characterized by a continued in-
crease in myocardial stiffness, that is, diastolic dysfunction.
The summation of remodeling events as they relate to mal-
adaptive phases of AS and LVH, and their temporal relation
to the development of heart failure and AVR, are shown in
Figure 3. As depicted by the hypothetic figure, cellular and
ECM remodeling occurs during the progression of AS. In
addition, clinical studies suggest that myocardial fibrosis
persists after AVR for AS and highlights potential inadequa-
cies of current treatment guidelines. Identification of a ma-
trix biomarker that reflects the transition to maladaptive
remodeling in the setting of LV pressure overload may
provide an opportunity to achievemore complete regression
of deleterious changes within the ECM at the time of AVR.
Targeting the ECM, and identification of just such
a biomarker, may ultimately provide clinicians with
a more precise means by which they are able to assessThe Journal of Thoracic and Caand counsel their patients with severe, though perhaps
asymptomatic, AS.References
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